1. Home
  2. ACLX

as 10-24-2025 3:51pm EST

$
-
-
.
-
-
+
$
-
.
-
-
+
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.

Founded: 2015 Country:
United States
United States
Employees: N/A City: REDWOOD CITY
Market Cap: 4.4B IPO Year: 2022
Target Price: $113.08 AVG Volume (30 days): 548.8K
Analyst Decision: Strong Buy Number of Analysts: 12
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -3.43 EPS Growth: N/A
52 Week Low/High: $47.86 - $107.37 Next Earning Date: 11-07-2025
Revenue: $56,979,000 Revenue Growth: -60.63%
Revenue Growth (this year): -59.13% Revenue Growth (next year): 210.73%

ACLX Daily Stock ML Predictions

Stock Insider Trading Activity of Arcellx Inc. (ACLX)

Name Ticker Relationship Date Transaction AVG Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Gilson Michelle ACLX CHIEF FINANCIAL OFFICER Oct 15 '25 Sell $91.04 5,364 $488,315.49 8,466
Gilson Michelle ACLX CHIEF FINANCIAL OFFICER Oct 6 '25 Sell $86.22 1,064 $91,733.29 8,466
Gilson Michelle ACLX CHIEF FINANCIAL OFFICER Oct 3 '25 Sell $86.00 4,882 $419,869.58 8,466
Heery Christopher ACLX CHIEF MEDICAL OFFICER Sep 30 '25 Sell $81.40 21,034 $1,709,722.59 624
Heery Christopher ACLX CHIEF MEDICAL OFFICER Sep 29 '25 Sell $80.16 73 $5,851.68 624

Share on Social Networks: